## Fabio Valenti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2921295/publications.pdf

Version: 2024-02-01

|          |                | 1163117      | 1588992        |
|----------|----------------|--------------|----------------|
| 8        | 645            | 8            | 8              |
| papers   | citations      | h-index      | g-index        |
|          |                |              |                |
|          |                |              |                |
| 0        | O              | O            | 1220           |
| 8        | 8              | 8            | 1230           |
| all docs | docs citations | times ranked | citing authors |
|          |                |              |                |

| # | Article   | IF   | CITATIONS |
|---|---|------|-----------|
| 1 | Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease. Seminars in Cell and Developmental Biology, 2020, 98, 105-117.  | 5.0  | 33        |
| 2 | The miR-205-5p/BRCA1/RAD17 Axis Promotes Genomic Instability in Head and Neck Squamous Cell Carcinomas. Cancers, 2019, 11, 1347.  | 3.7  | 31        |
| 3 | Long Non-coding MIR205HG Depletes Hsa-miR-590-3p Leading to Unrestrained Proliferation in Head and Neck Squamous Cell Carcinoma. Theranostics, 2018, 8, 1850-1868.  | 10.0 | 65        |
| 4 | <scp>YAP</scp> enhances the proâ€proliferative transcriptional activity of mutant p53 proteins. EMBO Reports, 2016, 17, 188-201.  | 4.5  | 154       |
| 5 | Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget, 2015, 6, 5547-5566.   | 1.8  | 41        |
| 6 | Selected items from the Charcot-Marie-Tooth (CMT) Neuropathy Score and secondary clinical outcome measures serve as sensitive clinical markers of disease severity in CMT1A patients. Neuromuscular Disorders, 2014, 24, 1003-1017. | 0.6  | 25        |
| 7 | Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurology, The, 2011, 10, 320-328.   | 10.2 | 222       |
| 8 | Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle, 2011, 10, 4330-4340.   | 2.6  | 74        |